NeoGenomicsNASDAQ: NEO

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (T S X V : NBM) (OTC: NBMFF)

Although the financial results of NeoGenomics (NEO) for the quarter ending March 2024 provide an overview of the company's performance, it may be beneficial to analyze how certain key metrics stack up against Wall Street predictions and the previous year's figures.

NeoGenomics reported a quarterly loss of $0.02 per share, which was better than the expected loss of $0.03 per share according to Zacks. This is an improvement from the loss of $0.09 per share reported in the same quarter last year.

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript

NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.06 per share a year ago.